{‘She has no experience’: this American scientific community braces for Dr. Høeg's tenure at the FDA.

As the United States continues making sweeping revisions to its vaccination guidelines, a particular individual has emerged in a surprising turn: Høeg, a US-based sports medicine doctor and epidemiologist who rose to prominence by questioning Covid vaccines throughout the pandemic and has zeroed in on alleged deaths following Covid immunization in her recent position at the US Food and Drug Administration (FDA).

Proposed Overhauls to Childhood Vaccine Program

Public health authorities planned to announce sweeping revisions to the pediatric vaccine schedule in December, bringing the US with the Danish vaccine program, it is understood – a substantial departure that would place the US out of step with much of the world with little proof for benefit. The planned update has been delayed until the coming year.

Rather than the director of the vaccine center, Dr. Høeg is set to present at the gathering. She was newly appointed temporary leader of the FDA’s drug evaluation center, the fifth individual to lead the office this year.

A New Direction at the FDA

Høeg's temporary position might represent a closer partnership between the drug and vaccine divisions as Dr. Høeg and Dr. Prasad strengthen their influence at the agency – and it suggests a renewed priority upon reevaluating previously authorized immunizations at the FDA.

Dr. Høeg has often pushed for ending some childhood immunization guidelines in the US so as to align more in line with Denmark, a society with nationalized medicine and a citizenry roughly the size of Wisconsin’s.

So far comments, she has kept her attention on vaccines – traditionally the domain of Dr. Prasad, chief of the FDA’s vaccine center – as opposed to drug regulation.

Doubts Over Expertise

Dr. Høeg has little discernible experience in drug development, approval processes or administrative roles, which has been customary for former directors of the Center for Biologics Evaluation and Research. She has worked at the FDA as a senior adviser to the agency head and CBER since spring.

“She appears not to have any of the qualifications” for leading the drug-regulation department, said Dr. Jonathan Howard. “She has not conducted a clinical trial. She lacks experience in leading a sizeable institution. She is not an expert in pharmaceutical oversight.”

Previous heads of CBER would “be deeply familiar with laws and regulations and the research of pharmaceutical innovation”, commented Dr. Janet Woodcock. “Clearly, she lacks the sort of resume that former directors who led CBER have had.”

The drug center has an immense portfolio at the agency, the former commissioner emphasized.

“Many people just zeroes in on the innovative therapies, but the generic drug division clears numerous off-brand pharmaceuticals. There’s a biosimilars division, OTC medication office and so forth, and each of these need to be supervised,” Dr. Woodcock said. “The responsibility you neglect, that is the part that I always told people is going to bite you.”

Additionally, a significant management element to the position, which supervises over 5,000 staff members. “It’s a huge administrative position, if you execute it properly,” Woodcock added.

Response and Controversial Programs

In response to inquiries about Dr. Høeg's qualifications and whether this selection signifies greater collaboration among agency officials on vaccines, a press secretary stated that the “inquiries stem from inaccurate presumptions”.

“Her resume is consistent with the responsibilities of her position,” the spokesperson stated, citing the period Dr. Høeg spent counseling the agency head on “drug safety and oversight research, including predictive safety algorithms and shot safety tracking”.

As the temporary head, Dr. Høeg assumes responsibility for the commissioner’s recently launched expedited review system, a controversial one-day medication authorization process that allegedly worried her predecessors. “By what process are these medications being chosen for this voucher program? Who is making the calls?” Dr. Howard questioned. “There is a lot of lack of transparency occurring at the FDA right now.”

Overall, he said, “the Food and Drug Administration appears to be shifting towards more relaxed oversight of pharmaceuticals, aside from vaccines.”

Established History on Immunizations

Regarding immunizations, Høeg has a more documented, if troubling, history, critics said. She published a research paper using unconfirmed public submissions to determine the frequency of myocarditis following Covid vaccination. She consulted for the state of Florida chief medical officer Joseph Ladapo, who reportedly have modified findings to imply COVID-19 vaccinations are more dangerous than they are.

Part of her “desired changes” for the current government featured altering regulations for novel immunizations and discontinuing “unnecessary” vaccines, she stated post-election on a audio program. At the FDA, Dr. Høeg has reportedly suggested preventing adolescent males from getting Covid vaccinations.

“She is an all-around true believer who commences with her conclusions and works backwards to fit the evidence in a highly disingenuous, untruthful fashion,” Dr. Howard said.

Consolidating Power and a “Campaign of Retribution”

Høeg aligned with other dissenters, {like|